Development of a Novel Gene Therapy Strategy for SCID-X1 and a Method for Measuring Gene Targeting Outcomes at Endogenous Loci

dc.contributor.advisorBrown, Kathlynn C.en
dc.contributor.committeeMemberPorteus, Matthew H.en
dc.contributor.committeeMemberWright, Woodring E.en
dc.contributor.committeeMemberZinn, Andrew R.en
dc.creatorKildebeck, Eric Jamesen
dc.date.accessioned2018-06-04T18:51:23Z
dc.date.available2018-06-04T18:51:23Z
dc.date.created2016-05
dc.date.issued2016-04-05
dc.date.submittedMay 2016
dc.date.updated2018-06-04T18:42:40Z
dc.description.abstractTwo decades of gene therapy trials for primary immunodeficiencies have seen tremendous clinical success with a significant majority of patients developing functional immune systems. The development of leukemia in some patients has led to the development of precise gene targeting tools to correct genetic deficits without inducing genomic instability. In this thesis I report the development of a novel gene therapy strategy for SCID-X1 and the development of a useful method for measuring gene editing outcomes at endogenous loci in any cell type. TALENs designed to target IL2RG exon 1 are shown to be highly active and stimulate precise integration of IL2RG cDNA under the control of the endogenous IL2RG promoter. Activity levels of IL2Rγ in cells targeted with a codon-optimized cDNA and an artificial intron are also shown to be as high or higher than WT levels, demonstrating the potential for this approach to correct the functional deficit seen in SCID-X1. Furthermore, these TALENs successfully stimulate gene targeting in CD34+ hematopoietic stem and progenitor cells at frequencies 10-fold higher than the highest levels previously reported, while displaying less toxicity than ZFNs already in use in clinical trials. The high activity and low toxicity of these TALENs in combination with the potential for gene targeting at exon 1 to correct more than 98% of SCID-X1-causing mutations make this a promising strategy for gene therapy, which could one day form the basis for a safe and effective cure for SCID-X1.en
dc.format.mimetypeapplication/pdfen
dc.identifier.oclc1038532923
dc.identifier.urihttps://hdl.handle.net/2152.5/5303
dc.language.isoenen
dc.subjectGene Targetingen
dc.subjectGenetic Therapyen
dc.subjectInterleukin Receptor Common gamma Subuniten
dc.subjectX-Linked Combined Immunodeficiency Diseasesen
dc.titleDevelopment of a Novel Gene Therapy Strategy for SCID-X1 and a Method for Measuring Gene Targeting Outcomes at Endogenous Locien
dc.typeThesisen
dc.type.materialtexten
thesis.degree.departmentGraduate School of Biomedical Sciencesen
thesis.degree.disciplineCancer Biologyen
thesis.degree.grantorUT Southwestern Medical Centeren
thesis.degree.levelDoctoralen
thesis.degree.nameDoctor of Philosophyen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
KILDEBECK-DISSERTATION-2016.pdf
Size:
32.74 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description: